Prices rising for the same drug across multiple pharmaceutical companies might be the result of collusion, according to a letter sent to the Department of Justice and the Federal Trade Commission from Senator Bernie Sanders, I-Vermont, and Representative Elijah Cummings, D-Maryland.
Prices rising for the same drug across multiple pharmaceutical companies might be the result of collusion, according to a letter sent to the Department of Justice (DOJ) and the Federal Trade Commission (FTC) from Senator Bernie Sanders, I-Vermont, and Representative Elijah Cummings, D-Maryland.
The expectation when a patent expires is that the drug price will drop as competition enters the market. However, prices of 3 different insulin products created by 3 different drug makers have risen steadily. Sometimes the price increases mirror one another, Sanders and Cummings wrote in a letter addressed to Attorney General Loretta E. Lynch and FTC Chair Edith Ramirez.
In the letter, they ask Lynch and Ramirez to investigate whether these companies are engaging in collusion, which is illegal, or otherwise anticompetitive behaviors.
“This is an issue of tremendous national significance,” Sanders and Cummings wrote, adding that the United States spent $322 billion in medical costs and reduced productivity because of diabetes and prediabetes in 2012. Nearly 30 million Americans have diabetes and the CDC has estimated that 86 million have prediabetes, which means they are at risk of progressing to type 2 diabetes.
Insulin products aren’t the only ones being scrutinized. The DOJ is already investigation more than a dozen companies to see if executives came to an agreement on price increases for approximately 2 dozen drugs, including a heart treatment and an antibiotic, reported Bloomberg. The first of the charges could be filed by the end of 2016.
The diabetes medications that Sanders and Cummings are drawing attention to are 2 insulins, Lantus from Sanofi and Humalog from Eli Lilly, as well as a top-selling dipeptidyl peptidase-4 (DPP-4) inhibitor Januvia, and its metformin combination, Janumet from Merck & Co. From 2002 to 2013, the price of insulin medications more than tripled.
“The market entry price of ‘follow-on’ insulin products, which largely duplicate existing drugs, are partially informed by the high prices of available therapies,” they wrote. “Patients and taxpayers may not realize the savings that could be gained if existing insulin products were less expensive.”
In addition to the financial savings for taxpayers, the high price of insulins mean many patients find their treatment increasingly unaffordable.
“We are concerned that the potential coordination by these drug makers may not simply be a case of ‘shadow pricing,’ but may indicate possible collusion, and we believe this egregious behavior warrants a thorough investigation,” Sanders and Cummings concluded in their letter.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More